They say that cannabis can help out patients with Ehlers-Danlos syndrome (EDS).
It marks the first time a case study of medical cannabis as a treatment for chronic pain has appeared in the highly-respected publication.
EDS often paralyzes patients and mainstream medics typically rely on opiods for treatment. Many patients end up with radical surgery and eventually confined to a wheelchair due to the continuously worsening paralysis.
According to reports, patients who self-medicate with cannabis experience the relief of waking up paralysed, some even cured. A survey of 500 patients with EDS in the United States found that 37% used cannabis therapeutically and according to the paper’s author Sabeera Dar, of University College London Medical School, there is growing evidence for this in the UK and elsewhere too.
Dar writes that she hopes to “shed more light on this subject” to support a better understanding of the “improved clinical outcome” in patients.
This is the first BMJ case report that attempts to quantify the multifaceted benefits given by cannabinoid medication to a multisystem condition. It explores how chronic pain impacts many aspects of life and for this reason urges the profession to embark on further research on medical cannabis as a potential solution.
The key findings in this case report stem from the patient stories. The use of medical cannabis rapidly alleviated long standing chronic pain to dramatically reduce side effects related to opioid medication as these became less necessary to take.
PLEA has been publishing case studies of those rare conditions for which cannabis is transformational where nothing else is. The lack of clinical evidence preventing doctors from prescribing suggests that adopting a “patient-centred approach” to research, will allow for “vast swathes of reports illustrating the therapeutic benefits of medical cannabis” and ultimately begin to clarify which patients could benefit the most.
Understanding the day to day impact of these cannabinoid and terpene medicines is quite important. They are not like other medications where it just affects one aspect of your condition. Cannabis is so holistic and only case studies will truly show the wide ranging impact they have on the patient’s quality of life, but also on their family and all aspects of their care.
THC-O is a borderline psychedelic and cosmically powerful THC varient only recently been discovered
THC-O is a derivative of cannabis and it’s said to be 300% more powerful than the most astronomical THC. Curious potheads, While THC-O might be the holy grail to varsity stoners due to its high potency, several individuals are trying to understand its medicinal properties. Believing just maybe its medicinal properties will be just as powerful. Most especially for consumers who need to medicate with something stronger than the usual dispensary fare.
THC-O or THC-O acetate is a synthetic derivative (simply put, chemical twin) of THC. What this means is that while THC-O is truly a cannabinoid, it is not naturally occurring. THC-O is produced through a chemical process via contemporary cannabis tech and a toxic chemical known as acetic anhydride. The overall process converts 9 THC into THC-O acetate.
To produce THC-O, a series of extractions must first take place. First on the list is the extraction of cannabidiol from less than 0.3% THC hemp. Next, is the extraction of delta-8 THC from the CBD that was first extracted. Last, the organic solvent, acetic anhydride, is introduced to the delta-8. THC molecules. This helps to remove all flavonoids and terpenes leaving behind a scentless, flavorless, and oil-thick THC isolate with polarizing efficacy.
Presently, data, regulations, and research on THC-O acetate and its effects are minimal. However, researchers have inferred that THC-O is a prodrug. Meaning, it needs to be metabolized before it is activated. Immediately THC-O is metabolized, what’s left is a variation of delta-9 THC which is absorbed and transported within the body. Scientists speculated that the increase in potency is a result of its bioavailability. The fact that it does not contain any delta-9 THC also makes it legal for use.
The chemical composition and potency of THC-O do indicate an uncertain future.
Even though THC-O is produced from hemp, THC-O continues to exist in a gray area. This will allow THC-O to easily slip under the regulatory radar for the time being. With that being said, there are several reputable hemp brands presently advertising their THC-O products for purchase online. While the potency of the THC-O may prompt the curiosity of stoners for recreational use, there’s still the need to be cautious. THC-O not being a naturally occurring cannabinoid raises concerns considering its very volatile manufacturing process.
In the past, the market has seen some synthetic versions of THC . For instance, the K2 and Spice in the early 2000s were popular synthetic cannabinoids but were completely different from naturally occurring cannabinoids. As a result, the use of synthetic cannabinoids drove caution into the hearts of many. But unlike Spice and K2, THC-O chemically shares some similarities with delta-9 THC and delta-8 THC. They are all manufactured from cannabis unlike the synthetic cannabinoid produced in the 2000s.
However, most information discourages the smoking of THC-O altogether. This is because THC-O is considered a prodrug — a chemical that needs to metabolize before taking effect. On the other hand, Anecdotal data suggests THC-O has significant therapeutic potential when used instead of an edible tincture. This is good news for cannabis patients and an answer to the challenge of the ever-increasing THC tolerances of patients during chronic pain management. THC-O products could help improve the lifestyle of patients more elegantly than the usual recreational doses.
Presently no data suggests THC-O is particularly dangerous. And on the other hand, no data supports THC-O being particularly safe either. Therefore, if you will be experimenting with THC-O, do it with caution.